Table 1.

Overview of the Ebola_Tx trial.

Main funder	European Union
Sponsor	Institute of Tropical Medicine, Antwerp
Study site	Conakry, Guinea
Study design/phase	Phase III, non-randomized, comparative study
Inclusion criteria	Confirmed Ebola virus disease—all ages, including pregnant women and infants
Exclusion criteria for receipt of convalescent plasma	History of allergic reaction to blood or blood products
	Medical condition that precludes transfusion (e.g. decompensated heart failure)
	Patients arriving in a close to terminal condition
	Conditions that would jeopardize the safety of treating staff (e.g. agitated patient)
Intervention	Two units of convalescent plasma given consecutively (adults: 2 × 200–250 mL; children: total 10 mL/kg), with each unit from a different donor
	Titers of neutralizing antibodies were not known at time of administration (unselected convalescent plasma)
Primary outcome	Survival at 14 days post administration of convalescent plasma
Secondary outcomes	Survival at 30 days
	Serious adverse reactions
	Change in viral load after convalescent plasma treatment
	Safety risks in health workers
	Risk factors for mortality